Scholar Rock Holding Corporation Common Stock (SRRK)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$3.14 (+7.50%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Scholar Rock Holding Corporation Common Stock (SRRK)
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Key Insights

Critical company metrics and information

  • Share Price

    $43.59

  • Market Cap

    $4.08 Billion

  • Total Outstanding Shares

    93.62 Million Shares

  • Total Employees

    150

  • Dividend

    No dividend

  • IPO Date

    May 24, 2018

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Homepage

    https://www.scholarrock.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$8.59 Million
Net Cash Flow From Operating Activities, Continuing$-188.78 Million
Net Cash Flow$8.59 Million
Net Cash Flow From Financing Activities$103.19 Million
Net Cash Flow From Investing Activities$94.19 Million
Net Cash Flow From Financing Activities, Continuing$103.19 Million
Net Cash Flow From Operating Activities$-188.78 Million
Net Cash Flow From Investing Activities, Continuing$94.19 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Basic Average Shares$292.99 Million
Diluted Average Shares$292.99 Million
Income/Loss From Continuing Operations Before Tax$-225.97 Million
Net Income/Loss$-225.97 Million
Revenues$0.00
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Research and Development$169.15 Million
Depreciation and Amortization$2.21 Million
Diluted Earnings Per Share$2.35
Other Operating Expenses$60.31 Million
Net Income/Loss Available To Common Stockholders, Basic$-225.97 Million
Preferred Stock Dividends And Other Adjustments$0.00
Nonoperating Income/Loss$4.76 Million
Operating Expenses$230.73 Million
Operating Income/Loss$-230.73 Million
Basic Earnings Per Share$2.35
Income/Loss From Continuing Operations After Tax$-225.97 Million
Net Income/Loss Attributable To Parent$-225.97 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Equity$79.20 Million
Other Current Liabilities$25.33 Million
Liabilities$99.94 Million
Assets$179.13 Million
Noncurrent Liabilities$60.56 Million
Wages$9.97 Million
Liabilities And Equity$179.13 Million
Other Non-current Assets$23.05 Million
Accounts Payable$4.07 Million
Current Assets$152.93 Million
Equity Attributable To Parent$79.20 Million
Fixed Assets$3.16 Million
Current Liabilities$39.37 Million
Noncurrent Assets$26.21 Million
Equity Attributable To Noncontrolling Interest$0.00

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.